| Autor: |
Shamrey VK; Kirov military medical Academy, St. Petersburg, Russia., Kurasov ES; Kirov military medical Academy, St. Petersburg, Russia., Nechiporenko VV; Kirov military medical Academy, St. Petersburg, Russia., Kolchev AI; Kirov military medical Academy, St. Petersburg, Russia., Tsygan NV; Kirov military medical Academy, St. Petersburg, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (5), pp. 160-164. |
| DOI: |
10.17116/jnevro2020120051160 |
| Abstrakt: |
A review of the current literature on the possible use of mexidol (ethylmethylhydroxypyridine succinate) in the treatment of mental (including addictive) disorders is conducted. The possibility of its use to reduce negative psychopathological symptoms, neurocognitive deficit, manifestations of the antipsychotic syndrome (including its extrapyramidal disorders) in antipsychotic treatment of patients with schizophrenia spectrum disorders and insomnia disorders in the complex therapy of borderline mental disorders has been shown. The potential of mexidol in the treatment of addictive pathology, as well as the effects of intoxication caused by alcohol and other psychoactive (including narcotic) substances, deserves special attention. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
